Free Trial
NASDAQ:ECOR

electroCore Q2 2025 Earnings Report

electroCore logo
$6.88 -0.67 (-8.87%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$7.37 +0.49 (+7.11%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

electroCore EPS Results

Actual EPS
N/A
Consensus EPS
-$0.32
Beat/Miss
N/A
One Year Ago EPS
N/A

electroCore Revenue Results

Actual Revenue
N/A
Expected Revenue
$7.24 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

electroCore Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

electroCore Earnings Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
electroCore, Inc. (ECOR): A Bull Case Theory
See More electroCore Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like electroCore? Sign up for Earnings360's daily newsletter to receive timely earnings updates on electroCore and other key companies, straight to your email.

About electroCore

electroCore (NASDAQ:ECOR) is a commercial-stage bioelectronic medicine company focused on the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies. Founded in 2006, the company has its headquarters in Basking Ridge, New Jersey, and was established with the aim of harnessing the therapeutic benefits of neuromodulation without the need for implantable devices. Since its inception, electroCore has advanced a pipeline of products designed to address a range of neurological and inflammatory conditions.

The company’s flagship product, gammaCore, is a handheld, battery-powered device that delivers controlled electrical stimulation to the cervical branch of the vagus nerve. gammaCore has received regulatory clearances in the United States, Europe and other markets for the acute and preventive treatment of migraine and cluster headaches. The therapy is administered by placing the device against the side of the neck, offering patients a drug-free alternative that can be self-administered in home or clinical settings.

electroCore has established a growing commercial presence in North America and Europe through a combination of direct sales, specialty distributors and partnerships with healthcare providers. The company continues to pursue label expansions and additional regulatory approvals in other indications, including inflammatory and respiratory disorders. Clinical programs are underway to explore gammaCore’s potential in conditions such as gastrointestinal diseases, heart failure and depression, reflecting the broader applicability of nVNS technology.

Under the leadership of Chairman and Chief Executive Officer Jonathan Sackier, electroCore’s management team brings experience in medical devices, pharmaceuticals and global commercialization. The company maintains a focus on scaling operations, strengthening payer reimbursement pathways and advancing research collaborations. With an emphasis on innovation and patient access, electroCore seeks to establish nVNS as a foundational therapy in bioelectronic medicine.

View electroCore Profile

More Earnings Resources from MarketBeat